TGFB1 and neoplasm: Blockade of the TGFβ signaling has shown promising prospects in cancer therapy [21, 38, 43, 46], due to attenuation of the Treg-mediated immunosuppression, increase in the T cell cytotoxicity, facilitating of the T cell penetration into the center of the tumor, as well as inhibition of epithelial-mesenchymal transition, resulting in vigorous anti-tumor immunity and tumor regression [21].